CGTN
17.9.2020 12:03:22 CEST | Business Wire | Press release
China has vowed to eradicate absolute poverty in rural areas by the end of 2020 despite the COVID-19 epidemic. While efforts are being made to ensure "no single poor area or individual shall be left behind" – as President Xi Jinping puts it – people that have recently shaken off poverty are striving for a better life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005399/en/
Among the 529 residents in a small village in central China's Hunan Province, 95 in 30 households used to live under the poverty line. The whole village was lifted out of poverty through rural tourism in 2018, and the average annual income of the residents reached 13,840 yuan (about 2,060 U.S. dollars) last year – way above the national poverty line of 2,300 yuan (about 340 U.S. dollars).
Shazhou Village, located in a mountainous area in Rucheng County, Chenzhou City, was the first stop of Xi's inspection tour in Hunan.
Xi, also general secretary of the Communist Party of China (CPC) Central Committee, visited the village on Wednesday and learned about poverty relief industries and progress in consolidating poverty eradication at a modern agricultural tourism demonstration base.
Targeted poverty alleviation
China has adopted a targeted approach in its poverty alleviation campaign, which means taking tailored relief measures to fit different local conditions.
The story of Shazhou is a prime example of that approach. The village boasts the beautiful scenery of the Luoxiao Mountains and the unique Yao ethnic culture – nearly two thirds of the residents belong to the Yao ethnic group. Tourism has played a significant role in Shazhou's battle against poverty.
The village has promoted rural tourism and high-quality fruit planting, and arranged training programs to help villagers obtain such job skills as for restaurant cooks and rural tourism industry employees. More than 350 local jobs have been created through the efforts.
With all its residents lifted out of poverty, Shazhou has also been known for such national-level honor as the "village of beauty and leisure," "role model for ethnic unity and progress," "key village for promoting rural tourism" and "traditional Chinese village."
New starting point
Since the 18th CPC National Congress in late 2012, China has achieved remarkable results in poverty reduction. More than 93 million rural people shook off poverty between 2013 and 2019.
But 5.51 million people needed to get rid of poverty by the end of 2019. And such a formidable task was coincided by accident with the coronavirus outbreak.
Speaking at a symposium on poverty alleviation in March, Xi described the goal of ending absolute poverty by 2020 as a "solemn pledge" made by the CPC Central Committee to the Chinese people, urging authorities at all levels to deliver on that promise.
As China intensifies efforts in the final stage of the tough battle, Xi tours around the country to inspect economic and social development, with poverty alleviation high on the agenda. Prior to the Hunan trip, he had taken inspection tours this year of capital city Beijing and provinces of Yunnan, Hubei, Zhejiang, Shaanxi, Shanxi, Jilin and Anhui, and Ningxia Hui Autonomous Region.
In addition to increasing poor people's incomes, China is also striving to improve the quality of poverty relief. Xi has repeatedly called for efforts to ensure rural poor people do not have to worry about food and clothing and have access to compulsory education, basic medical services and safe housing.
Meanwhile, he is looking into the future beyond the end of poverty. "Being lifted out of poverty is not an end in itself but the starting point of a new life and a new pursuit," he said on several occasions this year, calling for consolidating achievements in poverty alleviation and advancing the rural vitalization strategy.
Put forward at the 19th CPC National Congress in 2017, the strategy aims to build rural areas with thriving businesses, pleasant living environments, social etiquette and civility, effective governance and prosperity.
Shazhou is among many previously poor villages in China that have embarked on the journey for a better future.
On Wednesday, Xi also visited a revolution-themed exhibition hall, a village service center, a clinic, a primary school and the homes of villagers in Shazhou.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005399/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
